Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biochem Pharma (BCHE) -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (754)	6/21/2000 4:57:00 PM
From: Shack	Read Replies (1) \| Respond to of 783

Hi Jim, you seem to be alone over here so i thought I'd throw in my two cents. I'm a trader (both day and position) and I have recently taken a heavy position in BCHE (actually in BCH on Toronto because I'm Canadian) call options. Here's a post I made over on Yahoo" For whatever reason, we are moving up here. I recently bought some calls based on the bullish chart. Volume is rising, we are above the 50 and 200 MA, and probably most importantly, we are still near the bottom of the large 5 year trading channel. One other interesting note. I notice that we are trading more shares on the Nasdaq now instead of the Toronto exchange. This has not historically been the case, check the quote/charts (BCH.TO is the Yhoo symbol for the Canuck stock) I'm not even sure what it means but it would a appear there is more interest coming form the U.S. now. Just thought I'd let you know that technically, things look better and better. Cheers, Shack

To: Jim Oravetz who wrote (754)	6/27/2000 12:33:00 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 783

BioChem Pharma Inc. (BCHE) has closed the sale of its interest in North American Vaccine Inc. (NVX) to Baxter International Inc. (BAX). In a news release, BioChem said Baxter is paying total consideration of C$210 million for BioChem's holdings in North American Vaccine, which include shares, a debenture, a line of credit and "related interest and premium." It said the consideration consists of C$86 million in cash and about 1.3 million Baxter shares. As reported, Baxter completed its US$6.73-a-share takeover of North American Vaccine Monday. Baxter International, Deerfield, Ill., makes blood and circulatory products. North American Vaccine, Beltsville, Md., is a vaccine research and development concern. Jim